| dc.creator | Jirathitikal,Vichai | |
| dc.creator | Metadilogkul,Orapun | |
| dc.creator | Bourinbaiar,Aldar S. | |
| dc.date | 2003-04-01 | |
| dc.date.accessioned | 2020-02-17T15:30:16Z | |
| dc.date.available | 2020-02-17T15:30:16Z | |
| dc.identifier | https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0717-34582003000100010 | |
| dc.identifier.uri | https://revistaschilenas.uchile.cl/handle/2250/128988 | |
| dc.description | V-1 Immunitor (V1) is an oral AIDS vaccine currently being used as a therapeutic modality by HIV-positive patients. Upon interim analysis of phase I safety trial it has been discovered that patients who had elevated liver enzymes aspartate (AST/SGOT) and alanine (ALT/SGPT) aminotransferases have experienced the reduction of enzyme levels back to normal. Two other hepatitis markers alkaline phosphatase and bilirubin have also decreased. V1 s effect may be hepatitis-specific since liver enzymes in normal patients treated with V1 have not changed and three patients who were Hepatitis B antigen positive at baseline became negative after therapy. The results suggest that V1 supplementation reduces hepatic damage caused by hepatitis viral infection. | |
| dc.format | text/html | |
| dc.language | en | |
| dc.publisher | Pontificia Universidad Católica de Valparaíso | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.source | Electronic Journal of Biotechnology v.6 n.1 2003 | |
| dc.title | Normalization of elevated liver enzymes due to V-1 Immunitor therapy | |
